WASHINGTON (AP) — The maker of OxyContin says it has completed testing of an abuse-resistant version of the painkiller hydrocodone, a surprise development that could derail sales of the recently launched Zohydro, a similar medication that has been criticized for lacking such safeguards.

Purdue Pharma says it plans to submit its extended-release hydrocodone drug to the Food and Drug Administration later this year. The company’s tablets are designed to prevent users from crushing them for snorting or injection.

Recommended Stories

Painkiller ban raises constitutional questions

FDA approves new painkiller from OxyContin maker

Why we support increasing access to naloxone